There was a greater reduction in major or clinically relevant nonmajor bleeding with apixaban compared with warfarin in East Asian ( HR 0.49 , 95 % CI 0.35-0 .67 ) than in non-East Asian ( HR 0.71 , 95 % CI 0.63-0 .79 ) patients ( interaction P = .03 ) .